Systematic Review of Linezolid Population Pharmacokinetics in Pediatric: Models, Covariates, and Dosing Implication

https://doi.org/10.22146/jmpf.108892

Firdhani Satia Primasari(1), Arief Rahman Hakim(2*)

(1) Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(2) Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(*) Corresponding Author

Abstract


Background: The increasing prevalence of bacterial resistance has positioned linezolid as a promising antibiotic for treating infections, including in pediatric patients. Knowledge of pharmacokinetic parameters is very useful in optimizing the dose to be used in patient therapy. However, pharmacokinetic data to guide optimized dosing in children remain limited.

Objectives: This review aims to summarize population pharmacokinetic (PopPK) models of linezolid in pediatric populations and identify significant covariates influencing its pharmacokinetics.

Methods: A systematic search was conducted in PubMed and ScienceDirect databases for studies published between 2014 and May 2025 using the keywords "linezolid", "population pharmacokinetics", and "pharmacokinetic model".

Results: Six studies met the inclusion criteria and were analysed. The pharmacokinetic models were mainly based on blood concentration measurements and constructed using NONMEM in four studies. Most studies employed one-compartment models. Clearance values ranged from 0.068 to 5.82 L/h, and volume of distribution from 0.783 to 10.5 L. Body weight consistently emerged as a significant predictor of clearance, while body surface area was associated with volume of distribution.

Conclusion: PopPK modeling highlights considerable variability in linezolid pharmacokinetics among pediatric patients, influenced primarily by weight and other covariates. Further studies are needed to compare oral versus IV formulations and to incorporate unbound (free) drug concentrations for improved dose optimization in pediatric populations.


Keywords


linezolid; pediatric; population pharmacokinetic

Full Text:

PDF


References

  1. Wilson DN, Schluenzen F, Harms JM, Starosta AL, Connell SR, Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci U S A. 2008;105(36):13339-13344. doi:10.1073/pnas.0804276105
  2. Hashemian SMR, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther. 2018;12:1759-1767. doi:10.2147/DDDT.S164515
  3. Azzouz A, Preuss CV. Linezolid. In: StatPearls. StatPearls Publishing; 2025. Accessed June 25, 2025. http://www.ncbi.nlm.nih.gov/books/NBK539793/
  4. Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015;7(4):603-615. doi:10.3978/j.issn.2072-1439.2015.03.10
  5. Zahedi Bialvaei A, Rahbar M, Yousefi M, Asgharzadeh M, Samadi Kafil H. Linezolid: a promising option in the treatment of Gram-positives. J Antimicrob Chemother. 2017;72(2):354-364. doi:10.1093/jac/dkw450
  6. Roger C, Roberts JA, Muller L. Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones. Clin Pharmacokinet. 2018;57(5):559-575. doi:10.1007/s40262-017-0601-x
  7. Qin Y, Zhang LL, Ye YR, Chen YT, Jiao Z. Parametric population pharmacokinetics of linezolid: A systematic review. Br J Clin Pharmacol. 2022;88(9):4043-4066. doi:10.1111/bcp.15368
  8. Hui LA, Bodolea C, Popa A, Vlase AM, Hirișcău EI, Vlase L. Linezolid Pharmacokinetics in Critically Ill Patients: Continuous Versus Intermittent Infusion. Antibiotics. 2024;13(10):961. doi:10.3390/antibiotics13100961
  9. Richards GA, Brink AJ. Therapeutic drug monitoring: linezolid too? Crit Care. 2014;18(5):525. doi:10.1186/s13054-014-0525-x
  10. Yang M, Zhao L, Wang X, et al. Population Pharmacokinetics and Dosage Optimization of Linezolid in Critically Ill Pediatric Patients. Antimicrob Agents Chemother. 2023;95(5):e02504-20, AAC.02504-20. doi:10.1128/AAC.02504-20
  11. Tian X, Jiang T, Dong L, et al. Population pharmacokinetics and clinical assessment of linezolid in pediatric bacterial infections. Antimicrob Agents Chemother. 2025;69(5):e0129924. doi:10.1128/aac.01299-24
  12. Bandín-Vilar E, García-Quintanilla L, Castro-Balado A, et al. A Review of Population Pharmacokinetic Analyses of Linezolid. Clin Pharmacokinet. 2022;61(6):789-817. doi:10.1007/s40262-022-01125-2
  13. Heidari S, Khalili H. Linezolid pharmacokinetics: a systematic review for the best clinical practice. Eur J Clin Pharmacol. 2023;79(2):195-206. doi:10.1007/s00228-022-03446-4
  14. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. Published online March 29, 2021:n71. doi:10.1136/bmj.n71
  15. 7. Systematic reviews of etiology and risk - JBI Manual for Evidence Synthesis - JBI Global Wiki. Accessed August 22, 2025. https://jbi-global-wiki.refined.site/space/MANUAL/355598596/7.+Systematic+reviews+of+etiology+and+risk
  16. Garcia-Prats AJ, Schaaf HS, Draper HR, et al. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies. PLoS Med. 2019;16(4):e1002789. doi:10.1371/journal.pmed.1002789
  17. Ogami C, Tsuji Y, To H, Yamamoto Y. Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients. J Infect Chemother Off J Jpn Soc Chemother. 2019;25(12):979-986. doi:10.1016/j.jiac.2019.05.025
  18. Li SC, Ye Q, Xu H, Zhang L, Wang Y. Population Pharmacokinetics and Dosing Optimization of Linezolid in Pediatric Patients. Antimicrob Agents Chemother. 2019;63(4):e02387-18. doi:10.1128/AAC.02387-18
  19. Duan LF, Li JJ, Shen LR, et al. Therapeutic drug monitoring of linezolid in Chinese premature neonates: a population pharmacokinetic analysis and dosage optimization. Antimicrob Agents Chemother. 2024;68(11):e0114824. doi:10.1128/aac.01148-24
  20. Taylor ZL, Poweleit EA, Paice K, et al. Tutorial on model selection and validation of model input into precision dosing software for model‐informed precision dosing. CPT Pharmacomet Syst Pharmacol. 2023;12(12):1827-1845. doi:10.1002/psp4.13056
  21. Morales Castro D, Dresser L, Granton J, Fan E. Pharmacokinetic Alterations Associated with Critical Illness. Clin Pharmacokinet. 2023;62(2):209-220. doi:10.1007/s40262-023-01213-x
  22. Wang D, Zheng X, Yang Y, Chen X. Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count. Exp Ther Med. 2019;18(3):1786-1792. doi:10.3892/etm.2019.7747
  23. Abdelgawad N, Wasserman S, Abdelwahab MT, et al. Linezolid Population Pharmacokinetic Model in Plasma and Cerebrospinal Fluid Among Patients With Tuberculosis Meningitis. J Infect Dis. 2024;229(4):1200-1208. doi:10.1093/infdis/jiad413
  24. Soraluce A, Barrasa H, Asín-Prieto E, et al. Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation. Pharmaceutics. 2020;12(1):54. doi:10.3390/pharmaceutics12010054
  25. Li S, Wang Y, Dong H, et al. Population Pharmacokinetics and Dosing Regimen Optimization of Linezolid in Cerebrospinal Fluid and Plasma of Post-operative Neurosurgical Patients. J Pharm Sci. 2023;112(3):884-892. doi:10.1016/j.xphs.2022.12.016
  26. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J. 2003;22(9):S153. doi:10.1097/01.inf.0000086954.43010.63
  27. Barrasa H, Soraluce A, Usón E, et al. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective. Int J Infect Dis. 2020;93:329-338. doi:10.1016/j.ijid.2020.02.044
  28. Gijsen M, Vlasselaers D, Spriet I, Allegaert K. Pharmacokinetics of Antibiotics in Pediatric Intensive Care: Fostering Variability to Attain Precision Medicine. Antibiotics. 2021;10(10):1182. doi:10.3390/antibiotics10101182
  29. Zhou CC, Huang F, Zhang JM, Zhuang YG. Population Pharmacokinetics of Tigecycline: A Systematic Review. Drug Des Devel Ther. 2022;16:1885-1896. doi:10.2147/DDDT.S365512



DOI: https://doi.org/10.22146/jmpf.108892

Article Metrics

Abstract views : 213 | views : 43

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats